Print

Isconova Appoints Sven Andreasson as New CEO  
2/23/2012 6:54:26 AM

UPPSALA, 23 February, 2012 -- Isconova AB, a leading international vaccine adjuvant company, is pleased to announce the appointment of Sven Andréasson as CEO of the Company, effective 1st March 2012. Sven, currently CEO of Beta-Cell NV in Brussels, succeeds Russell G. Greig, who has been acting CEO since August 2011.

Sven Andréasson has a strong background as a CEO for many years within both pharmaceutical and biotech companies; he was President & CEO of Active Biotech AB between 1999 and 2008. Prior to that he held several senior management positions within the international pharmaceutical industry, including as President and Vice President of mainly Swedish, French, Belgian and German companies in the Pharmacia Corporation. Sven has been appointed by the Board of Isconova with the main objectives of progressing key clinical studies, strengthening corporate development activities, and enhancing revenues from the current vaccine business.

Ulf Tossman, Chairman of Isconova AB, commented;

“Sven Andréasson has extensive industry experience from leading positions within the international pharmaceutical industry, including as President and CEO of Active Biotech. His business development skills, together with his proven track record for securing collaborations with international partners will be of great value to Isconova as we embark on the next stage of growth.”

Sven Andréasson, incoming CEO of Isconova AB, commented;

“Isconova’s proprietary Matrix M™ platform enabling technology has the potential to improve vaccines for both humans and animals, in an attractive, growing market where novel vaccines present a significant opportunity. The Company has a solid pipeline of early to late stage proprietary and partnered programmes and I look forward to being part of a strong management team to develop Isconova to its full potential.”

Russell G. Greig has been appointed Chairman of the Board of Directors of Isconova – see separate release.

For more information, please contact:

Ulf Tossman, Chairman of the Board of Isconova AB

Tel: +46 705-63 08 58, e-mail: ulf.innovative.advice@gmail.com

Russell G. Greig, acting CEO and member of the Board of Isconova AB

Tel: +1 610 220 9802, e-mail: russell.g.greig@gmail.com

Sven Andréasson, incoming CEO of Isconova AB

Tel: +46 701 60 60 60, e-mail: sven.andreasson@skynet.be

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden.

Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser. www.isconova.com


//-->